Greywolf Therapeutics
Andy Page is an experienced executive in the pharmaceutical industry, currently serving as Chief Operating Officer and Chief Business Officer at Greywolf Therapeutics since August 2023. Prior to this role, Andy was Chief Operating Officer at Beckley Psytech from October 2020 to November 2022, and held several key positions at Otsuka Pharmaceutical Companies Europe, including CEO and President, Regional Vice President for Commercial Excellence, and UK Managing Director from August 2014 to November 2020. Andy’s earlier experience includes serving as Strategy and Market Development Director for EMEA Emerging Markets at Johnson & Johnson and Business Unit Director at Janssen-Cilag Ltd, where responsibilities encompassed general management, P&L oversight, and strategic planning across multiple business units. Educational credentials include a BSc Hons in Pharmacology and Physiology from the University of Leeds, a program at MGSM Sydney, and the designation of Chartered Marketer from CIM.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.